Form 4: Pliant Therapeutics Director Gayle Crowell Granted 30,000 Stock Options

Pliant Therapeutics, Inc. Director Gayle Crowell was granted 30,000 stock options with a strike price of $1.61, vesting over time, as reported in a recent SEC Form 4 filing.

Summary

• Gayle A. Crowell, a Director of Pliant Therapeutics, Inc. (PLRX), was granted 30,000 derivative securities in the form of stock options.
• The options have an exercise price of $1.61 per share.
• The grant date for these options was June 5, 2025, and they expire on June 5, 2035.
• The options vest over time, with 25% vesting on October 1, 2025, 25% on January 1, 2026, and 25% on April 1, 2026.
• The remaining 25% will vest on the earlier of the one-year anniversary of the grant date (June 5, 2026) or the next annual meeting of stockholders.
• Vesting is contingent upon Ms. Crowell's continued service as a Director to the Issuer through each vesting date or the annual meeting.
• Following this transaction, Ms. Crowell beneficially owns 30,000 derivative securities directly.
• An accompanying Power of Attorney document authorizes specific individuals to execute SEC filings on behalf of Gayle Crowell.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive step to align their interests with long-term shareholder value, reflecting standard corporate governance practices and incentivizing continued commitment to the company's success.

Positives

• The grant of stock options to Director Gayle Crowell aligns her financial interests with the long-term performance and shareholder value of Pliant Therapeutics, Inc.
• Equity compensation is a standard practice to incentivize directors and retain talent.

Risks

• The value of the stock options is dependent on the future stock price of Pliant Therapeutics, Inc. exceeding the exercise price of $1.61.
• Vesting of the options is subject to Gayle Crowell's continued service as a Director, meaning unvested options would be forfeited if her service ceases prematurely.

Future Outlook

The option grant is a standard component of executive and director compensation, designed to incentivize long-term performance and align the director's interests with the company's future success and shareholder value creation. It implies an expectation of continued service from the director.

Industry Context

The granting of stock options to directors is a common and widely accepted practice across various industries, particularly in biotechnology and pharmaceutical sectors like Pliant Therapeutics. This form of equity compensation is used to attract, retain, and motivate key personnel by linking their personal wealth directly to the company's stock performance, thereby aligning their interests with those of shareholders.

Comparison to Industry Standards

• The grant of stock options to a director is a standard form of equity compensation in publicly traded companies, particularly in the life sciences sector, to align director incentives with shareholder value.
• While the specific number of options (30,000) and exercise price ($1.61) are unique to this grant, the mechanism of granting options with a vesting schedule tied to continued service is consistent with typical compensation structures seen at comparable biotech firms.

Stakeholder Impact

• Shareholders: The option grant aligns the director's interests with shareholder value, potentially leading to more focused decision-making aimed at increasing the company's stock price.
• Director (Gayle Crowell): Provides a significant long-term incentive and potential for personal wealth creation tied to the company's performance.

Next Steps

• Gayle Crowell's continued service as a Director is required for the options to vest according to the specified schedule.
• Upon vesting, Gayle Crowell will have the right to exercise the options and purchase shares of Pliant Therapeutics common stock at the exercise price of $1.61 per share.

Key Dates

Keywords

Pliant Therapeutics, PLRX, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Vesting Schedule, Corporate Governance